Pharming Group (NASDAQ:PHAR) and Oramed Pharmaceuticals (NASDAQ:ORMP) Head-To-Head Comparison

Pharming Group (NASDAQ:PHAR – Get Free Report) and Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Insider & Institutional Ownership

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 20.8% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Pharming Group has a beta of -0.05, suggesting that its share price is 105% less volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.

Profitability

This table compares Pharming Group and Oramed Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pharming Group 6.23% 8.70% 4.93%
Oramed Pharmaceuticals N/A -6.97% -6.01%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Pharming Group and Oramed Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharming Group 0 2 3 0 2.60
Oramed Pharmaceuticals 0 0 1 0 3.00

Pharming Group currently has a consensus target price of $39.67, indicating a potential upside of 220.41%. Given Pharming Group’s higher probable upside, analysts clearly believe Pharming Group is more favorable than Oramed Pharmaceuticals.

Earnings and Valuation

This table compares Pharming Group and Oramed Pharmaceuticals”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pharming Group $376.13 million 2.33 $2.85 million $0.32 38.69
Oramed Pharmaceuticals $2.00 million 80.24 $64.05 million $6.16 0.60

Oramed Pharmaceuticals has lower revenue, but higher earnings than Pharming Group. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

About Pharming Group

(Get Free Report)

Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system. Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).

About Oramed Pharmaceuticals

(Get Free Report)

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing oral drug-delivery technologies. Its platform is designed to protect protein-based medicines as they pass through the digestive system and support their absorption, with the aim of delivering medicines by mouth that have traditionally been given by injection. The company’s research has focused on oral treatments for metabolic conditions, including ORMD-0801, an oral insulin candidate, and an oral GLP-1 candidate. These products are investigational; Oramed does not market them as approved treatments.

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.